Addressing Limitations in Observational Studies of the Association Between Glucose-Lowering Medications and All-Cause Mortality: A Review

Drug Safety

Volumn 38, Issue 3, 2015, Pages 295-310

  Patorno, Elisabetta ^a   Garry, Elizabeth M ^a   Patrick, Amanda R ^a   Schneeweiss, Sebastian ^a   Gillet, Victoria G ^a   Zorina, Olesya ^b   Bartels, Dorothee B ^b,c   Seeger, John D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT;

CAUSE OF DEATH; DIABETES MELLITUS; HUMAN; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROCEDURES;

CAUSE OF DEATH; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; MORTALITY; OBSERVATIONAL STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84939996069     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0280-1     Document Type: Review

References (123)

1. Arana A, Rivero E, Egberts TCG. What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Pharmacoepidemiol Drug Saf. 2004;13:S330–1.
2. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–37.
3. Patorno E, Patrick AR, Garry EM, Schneeweiss S, Gillet VG, Bartels DB, et al. Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations. Diabetologia. 2014;57:2237–50.
4. Ray W. Observational studies of drugs and mortality. N Engl J Med. 2005;353:2319–21.
5. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
6. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.
7. Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;30:53–9.
8. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
9. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2012;14:23–9.
10. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf. 2010;19:858–68.
11. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev. 2004;20:239–45.
12. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411–8.
13. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ. 2009;339:b2942.
14. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008;29:166–76.
15. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601–10.
16. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
17. Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008;168:2368–75.
18. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492–9.
19. Hsiao FY, Tsai YW, Wen YW, Chen PF, Chou HY, Chen CH, et al. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010;19:786–91.
20. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51.
21. Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007;50:32–6.
22. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L. Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2008;29:177–84.
23. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract. 2009;86:247–53.
24. Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol. 2011;67:289–99.
25. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol. 2011;26:858–65.
26. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118:1202–11.
27. Yeh HT, Hsieh CF, Tsai YW, Huang WF. Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. Clin Ther. 2012;34:885–93.
28. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131:752–9.
29. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18:2905–12.
30. Loebstein R, Dushinat M, Vesterman-Landes J, Silverman B, Friedman N, Katzir I, et al. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol. 2011;51:173–80.
31. Olsson J, Lindberg G, Gottsäter M, Lindwall K, Sjöstrand A, Tisell A, et al. Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia. 2000;43:558–60.
32. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–8.
33. Evans JM, Doney AS, AlZadjali MA, Ogston SA, Petrie JR, Morris AD, et al. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010;106:1006–10.
34. Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174:169–74.
35. Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA. Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab. 2010;12:47–53.
36. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–5.
37. Choy-Shan A, Zinn A, Shah B, Danoff A, Donnino R, Schwartzbard AZ, et al. Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease. Coron Artery Dis. 2012;23:354–8.
38. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22:2640–5.
39. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:4605–12.
40. Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes. 2010;3:538–45.
41. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44.
42. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998.
43. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20:488–95.
44. Greenland S. Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology. 2003;14:300–6.
45. Azoulay L, Schneider-Lindner V, Dell’aniello S, Schiffrin A, Suissa S. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case–control study. Pharmacoepidemiol Drug Saf. 2010;19:335–42.
46. MacDonald MR, Eurich DT, Majumdar SR, Lewsey JD, Bhagra S, Jhund PS, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case–control study from the UK General Practice Research Database. Diabetes Care. 2010;33:1213–8.
47. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634–43.
48. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14:803–9.
49. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, et al. The risk of overall mortality in patients with type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis. Diabet Med. 2012;29:1029–35.
50. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46:145–54.
51. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis. Diabetes Care. 2010;33:1224–9.
52. Evans J, Ogston S, Emslie-Smith A, Morris A. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930–6.
53. Azoulay L, Schneider-Lindner V, Dell’aniello S, Filion KB, Suissa S. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case–control study. Pharmacoepidemiol Drug Saf. 2010;19:343–50.
54. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst. 2003;95:1797–800.
55. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14.
56. Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22:1–6.
57. Ray W. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–20.
58. Gamble JM, McAlister FA, Johnson JA, Eurich DT. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study. Value Health. 2012;15:191–7.
59. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59:1097–104.
60. Breslow NE, Day NE. Statistical methods in cancer research. Vol. II—the design and analysis of cohort studies. Lyon: International Agency for Research on Cancer; 1987.
61. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33:322–6.
62. Habib ZA, Tzogias L, Havstad SL, Wells K, Divine G, Lanfear DE, et al. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf. 2009;18:437–47.
63. Kahler KH, Rajan M, Rhoads GG, Safford MM, Demissie K, Lu SE, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care. 2007;30:1689–93.
64. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54.
65. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia. 2010;53:2546–53.
66. Andersson C, Gislason GH, Jørgensen CH, Hansen PR, Vaag A, Sørensen R, et al. Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract. 2011;94:119–25.
67. Hernan MA, Hernandez-Diaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med. 2013;159:560–2.
68. Hernan M, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55.
69. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
70. Jørgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention: a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54.
71. Robins J. Estimation of the time-dependent accelerated failure time model in the presence of confounding factors. Biometrika. 1992;79:321–34.
72. Hernan M, Brumback B, Robins J. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561–70.
73. Robins J, Hernan M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–60.
74. Robins J. A new approach to causal inference in mortality studies with sustained exposure periods: application to control of the healthy worker survivor effect. Math Model. 1986;7:1393–512.
75. Yang S, Eaton CB, Lu J, Lapane KL. Application of marginal structural models in pharmacoepidemiologic studies: a systematic review. Pharmacoepidemiol Drug Saf. 2014;23:560–71.
76. Walker AM. Confounding by indication. Epidemiology. 1996;7:335–6.
77. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10:577–81.
78. Walker AM. Observation and inference: an introduction to the methods of epidemiology. Chestnut Hill: Epidemiology Resources Inc.; 1991.
79. Wei M, Gaskill S, Haffner S, Stern M. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21:1167–72.
80. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151–7.
81. Lowe LP, Liu K, Greenland P, Metzger B, Dyer A, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care. 1997;20:163–9.
82. Gu K, Cowie C, Harris M. Mortality in adults with and without diabetes in a national cohort of the US population, 1971–1993. Diabetes Care. 1998;21:1138–45.
83. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85.
84. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.
85. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168–74.
86. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35:299–304.
87. Berger AK, Breall JA, Gersh BJ, Johnson AE, Oetgen WJ, Marciniak TA, et al. Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol. 2001;87:272–7.
88. Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol. 2001;24:151–8.
89. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–90.
90. Arruda-Olson AM, Patch RK 3rd, Leibson CL, et al. Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc. 2009;84:28–33.
91. Monami M, Balzi D, Lamanna C, et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007;23:479–84.
92. Horsdal HT, Johnsen SP, Søndergaard F, Jacobsen J, Thomsen RW, Schmitz O, et al. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev. 2009;25:515–22.
93. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32:1900–8.
94. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, et al. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev. 2006;22:477–82.
95. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18(10):2905–12.
96. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care. 2005;28:1680–9.
97. Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K. Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke. 2001;32:2029–32.
98. Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev. 2004;20:44–7.
99. Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. Am J Med Sci. 2008;336:241–7.
100. Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol. 2009;20:1094–101.
101. Vanasse A, Carpentier AC, Courteau J, Asghari S. Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diab Vasc Dis Res. 2009;6:87–93.
102. Sillars B, Davis WA, Hirsch IB, Davis TM. Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab. 2010;12:757–65.
103. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012;106:1374–8.
104. Schneeweiss S, Patrick AR, Stürmer T, Brookhart MA, Avorn J, Maclure M, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45:S131–42.
105. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–9.
106. Cepeda MS, Boston R, Farrar JT, Strom BL. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158:280–7.
107. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55.
108. D’Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–81.
109. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33–8.
110. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083–107.
111. Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies of causal effects. Stat Med. 2014;33:1685–99.
112. Freemantle N, Marston L, Walters K, Wood J, Reynolds MR, Petersen I. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research. BMJ. 2013;347:f6409.
113. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011;173:1404–13.
114. Rassen JA, Schneeweiss S. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf. 2012;21:41–9.
115. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart AM. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512–22.
116. Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55:1619–32.
117. Beckman T, Cuddihy R, Scheitel S, Naessens J, Killian J, Pankratz V. Screening mammogram utilization in women with diabetes. Diabetes Care. 2001;24:2049–53.
118. Fleming S, Pursley H, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005;43:132–40.
119. Zhao G, Ford E, Ahluwalia I, Li C, Mokdad A. Prevalence and trends of receipt of cancer screenings among US women with diagnosed diabetes. J Gen Intern Med. 2009;24:270–5.
120. Stergachis A. Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharm. 1988;22:157–61.
121. MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case–control study in New England. Cancer. 2011;117:1552–6.
122. West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142:1103–12.
123. West SL, Strom BL, Freundlich B, Normand E, Koch G, Savitz DA. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol. 1994;47:165–71.